

Online Repository Figures

INPRACTICE-D-18-00718, Platin chemotherapy hypersensitivity reactions: expanding the scope of practice and improving care

Amy Levin, MD^a, Gita Bhattacharya, BA^a, Kimberly Blumenthal, MD, MSc^{a,b}, Carlos A. Camargo, Jr., MD, DrPH^{a,c}, and Aleena Banerji, MD^a

FIGURE E1. Platin HSR risk stratification protocol

FIGURE E2. Intermediate desensitization protocol for oxaliplatin

References for Table 1

- E1. Zanutti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. *J Clin Oncol*. 2001;19:3126-9.
- E2. Meyer L, Zuberbier T, Worm M, Oettle H, Riess H. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. *J Clin Oncol*. 2002;20:1146-7.
- E3. Porzio G, Marchetti P, Paris I, Narducci F, Ricevuto E, Ficorella C. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. *Eur J Gynecol Oncol*. 2002;23:335-6.
- E4. Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. *Ann Oncol*. 2003;14:497-8.
- E5. Markman M, Zanutti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. *J Clin Oncol*. 2003;21:4611-4.
- E6. Moreno-Ancillo A, Domínguez-Noche C, Gil-Adrados AC, Cosmes PM, Duarte I, Mateos Y. Anaphylactoid reaction to carboplatin: successful "desensitization." *Allergol Immunopathol*. 2003;31:342-4.
- E7. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. *Cancer: Interdiscip Int J Am Cancer Soc*. 2003;97:2301-7.
- E8. Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. *Ann Allergy Asthma Immunol*. 2004;93:137-41.
- E9. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. *Gynecol Oncol*. 2004;95:370-6.

- E10. Confino □ Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. *Cancer: Interdiscip Int J Am Cancer Soc.* 2005;104:640-3.
- E11. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. *Gynecol Oncol.* 2005;99:393-9.
- E12. Herrero T, Tornero P, Infante S, Fuentes V, Sanchez MN, De Barrio M, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. *J of Investig Allergol and Clin Immunol.* 2006;16:327-30.
- E13. McAlpine JN, Kelly MG, O'Malley DM, Azodi M, Coombe K, Schwartz PE, et al. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies. *Gynecol Oncol.* 2006;103:288-92.
- E14. Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB. Oxaliplatin hypersensitivity: case report and successful repeat desensitization. *Am J of Ther.* 2007;14:116-8.
- E15. Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. *J Allergy Clin Immunol.* 2007;119:726-30.
- E16. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. *J Allergy Clin Immunol.* 2008;122:574-80.
- E17. Enrique E, Malek T, Castelló JV, De Mateo JA. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin. *Ann Allergy Asthma Immunol.* 2008;100:86.
- E18. Pagani M, Bonadonna P, Senna GE, Antico A. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. *Int Arch Allergy and Immunol.* 2008;145:54-7.
- E19. Gomez R, Harter P, Lück HJ, Traut A, Kommoss S, Kandel M, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. *Int J Gynecol Cancer.* 2009;19:1284-7.

- E20. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. *J of Allergy Clin Immunol.* 2009;123:1262-7.
- E21. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. *Clin Colorectal Cancer.* 2009;8:106-9.
- E22. Visitsunthorn N, Utsawapreechawong W, Pacharn P, Jirapongsananuruk O, Vichyanond P. Immediate type hypersensitivity to chemotherapeutic agents in pediatric patients. *Asian Pac J of Allergy and Immunol.* 2009;27:191-7.
- E23. Gottlieb GR, Bordoni RE, Lawhead RA, Feinberg BA. Successful outpatient desensitization of cancer patients with hypersensitivity reactions to chemotherapy. *Community Oncol.* 2010;10:452-7.
- E24. Herrera JM, Góngora-Melendez MA, Pineda-Maldonado ML, Medina-Sanson A, Chivardi JM, Del Río-navarro BE, et al. Carboplatin hypersensitivity and desensitization in an infant. *Ther Drug Monit.* 2010;32:525-8.
- E25. Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Anton J, Espinos J, et al. A new rapid desensitization protocol for chemotherapy agents. *J Investig Allergol Clin Immunol.* 2011;21:108-12.
- E26. Pagani M, Venemalm L, Bonnadona P, Vescovi PP, Botelho C, Cernadas JR. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. *Jpn J Clin Oncol.* 2012;42:347-50.
- E27. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. *J Allergy Clin Immunol.* 2012;129:443-7.
- E28. Caiado J, Castells M. Presentation and diagnosis of hypersensitivity to platinum drugs. *Curr Allergy Asthma Rep.* 2015;14:1-9.
- E29. Cortijo-Cascajares S, Nacle-López I, García-Escobar I, Aguilera-Vizcaíno MJ, Herreros-de-Tejada A, Castro HC, et al. Effectiveness of oxaliplatin desensitization protocols. *Clin and Transl Oncol.* 2013;15:219-25.
- E30. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. *Allergy.* 2013;68:853-61.

- E31. Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. *J of Allergy Clin Immunol: In Pract.* 2014;2:40-5.
- E32. Bruchim I, Goldberg A, Fishman A, Confino-Cohen R. Carboplatin hypersensitivity: evaluation and successful desensitization protocol. *Immunother.* 2014;6:905-12.
- E33. Martin-Lazaro J, Firvida JL, Berges-Gimeno P. Anaphylaxis after oxaliplatin allergy skin testing. *J Investig Allergol Clin Immunol.* 2014;24:269-70.
- E34. Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, Ureña-Tavera A, Zamora-Verduga M, Lopez-Gonzalez P, et al. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. *Allergy.* 2015;70:784-94.
- E35. D'Amelio CM, Aramendía JM, Yuste JR, Fusco JP, Gastaminza G, Goikoetxea MJ. Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity. *Ann Allergy Asthma Immunol.* 2015;114:534-5.
- E36. Wang AL, Patil SU, Long AA, Banerji A. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. *Ann Allergy Asthma Immunol.* 2015;115:422-8.
- E37. Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, et al. Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. *Gynecol Oncol.* 2017;144:77-82.
- E38. Brault F, Waton J, Poreaux C, Schmutz JL, Barbaud A. Hypersensitivity to platinum salts and taxanes: The value of skin tests and tolerance induction procedures. *Ann Dermatol Venereol.* 2017;144:685-95.
- E39. Galvão VR, Phillips E, Giavina-Bianchi P, Castells MC. Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. *J Allergy Clin Immunol: In Pract.* 2017;5:816-8.
- E40. Giavina-Bianchi P, Galvão VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. *J Allergy Clin Immunol: In Pract.* 2017;5:728-36.
- E41. Mawhirt SL, Sani S, Fonacier LS, Calixte R, Davis-Lorton MA, Aquino M. Skin testing results and induction of tolerance outcomes in platinum-sensitive patients. *J Allergy Clin Immunol.* 2017;139:AB36.

- E42. Solomon B, Colonna S. Recurrent cisplatin hypersensitivity reaction after first exposure: A case report. *J Oncol Pharm Pract.* 2017;1078155217735154.
- E43. Capelle H, Tummino C, Greillier L, Gouitaa M, Birnbaum J, Ausias N, et al. Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service. *J Clin Pharm Ther.* 2018;43:320-6.
- E44. Pérez-Rodríguez E, Martínez-Tadeo JA, Pérez-Rodríguez N, Hernández-Santana G, Callero-Viera A, Rodríguez-Plata E, et al. Outcome of 490 desensitizations to chemotherapy drugs with a rapid one-solution protocol. *J Allergy Clin Immunol: In Pract.* 2018;6:1621-7.

FIGURE LEGENDS**FIGURE E1. Platin HSR risk stratification protocol**

Because skin testing performed within 6 weeks of a reaction can be falsely negative, patients who are tested within this time frame begin with intermediate desensitization regardless of skin test results. For the remaining protocol, patients with negative skin testing who tolerate their desensitization can progress from intermediate to rapid to 50% inpatient infusion rate to 50% outpatient infusion rate.

FIGURE E2. Intermediate desensitization protocol for oxaliplatin

This is a sample intermediate desensitization protocol, based on our prior work. This protocol has 13 steps and takes approximately six hours to complete. The rate is increased every 15 minutes until step 12, at which the infusion is run for approximately 3 hours at the final rate of 80 milliliters per hour.

mL=milliliter, hr=hour, min=minute, mg=milligram

FIGURE E2. Intermediate desensitization protocol for oxaliplatin

Standard volume per bag: 250ml

Final rate of infusion: 80 ml/hr Time per step: 15 min

Level of severity: Intermediate Number of bags: 3 Total number of steps: 13

Calculated target concentration: 2.554 mg/ml Standard time of infusion: 187.5 minutes

Bag	Volume per bag (ml)	Concentration (mg/ml)	Total dose per bag (mg)	Amount of bag infused (ml)
1	250	0.02554	6.385	9.38
2	250	0.2554	63.85	18.75
3	250	2.53389	633.472	250

Step	Bag	Rate (ml/hr)	Time (min)	Cumulative Time (min)	Volume infused per step (ml)	Dose administered with this step (mg)	Cumulative dose (mg)	Fold increase per step
1	1	2.5	15	15	0.63	0.016	0.016	0
2	1	5	15	30	1.25	0.0319	0.0479	2
3	1	10	15	45	2.5	0.0639	0.1117	2
4	1	20	15	60	5	0.1277	0.2394	2
5	2	5	15	75	1.25	0.3193	0.5587	2.5
6	2	10	15	90	2.5	0.6385	1.1972	2
7	2	20	15	105	5	1.277	2.4742	2
8	2	40	15	120	10	2.554	5.0282	2
9	3	10	15	135	2.5	6.3347	11.3629	2.48
10	3	20	15	150	5	12.6694	24.0323	2
11	3	40	15	165	10	25.3389	49.3712	2
12	3	60	15	180	15	38.0083	87.3795	1.5
13	3	80	163.125	343.13	217.5	551.1205	638.5	1.33

FIGURE E1. Platin HSR risk stratification protocol

